Substance / Medication

Lenvatinib

Overview

Active Ingredient
lenvatinib
RxNorm CUI
1603296
Labeler: Eisai Inc.Updated: 2025-01-03T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

5 trials linked to this intervention

5
Total Trials
4
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Systematic meta-analysis of the toxicities and side effects of the targeted drug lenvatinib.
Liu Huihui, Wang Kai, Sun Yu et al. · Ann Med · 2026
PMID: 41439769Meta-AnalysisFull text (PMC)
Efficacy and Safety of Lenvatinib in Combination With Other Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma: A Meta-analysis.
Jamil Abdur, Qureshi Zaheer, Siddique Rimsha et al. · Am J Clin Oncol · 2025
PMID: 39439090Meta-Analysis
Efficacy and Safety of Lenvatinib versus Atezolizumab Plus Bevacizumab in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Remitha Ni Putu Sri Indrani, Dewi Ni Putu Rista Pradnya, Kusuma I Komang Wira Ananta et al. · Asian Pac J Cancer Prev · 2025
PMID: 40439364Meta-AnalysisFull text (PMC)
Efficacy of Lenvatinib Versus Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Remitha Ni Putu Sri Indrani, Dewi Ni Putu Rista Pradnya, Yogananda I Komang Chandra et al. · Asian Pac J Cancer Prev · 2025
PMID: 40542755Meta-AnalysisFull text (PMC)
Incidence and risk of hypertension and proteinuria in cancer patients treated with lenvatinib: a systematic review and meta-analysis.
Shibutani Yuma, Suzuki Atsuko, Imaoka Takuro et al. · Oncologist · 2025
PMID: 40632590Meta-AnalysisFull text (PMC)
An Indirect Treatment Comparison of Lenvatinib for the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma.
Ndirangu Kerigo, Paine Abby, Pilkington Hollie et al. · Adv Ther · 2025
PMID: 39680315Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Lenvatinib (substance)
SNOMED CT
714108002
UMLS CUI
C2986924
RxNorm CUI
1603296
Labeler
Eisai Inc.

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
5
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.